rapid-acting antidepressants

BPL-003 Shows Sustained TRD Relief in Phase 2a Trial

Beckley Psytech's BPL-003 phase 2a part 2 data shows lasting symptom reduction in treatment-resistant depression — what it means for the TRD landscape.